Literature DB >> 17186543

Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.

Tateo Sawabu1, Hiroshi Seno, Tomoko Kawashima, Akihisa Fukuda, Yoshito Uenoyama, Mayumi Kawada, Naoki Kanda, Akira Sekikawa, Hirokazu Fukui, Motoko Yanagita, Hiroshi Yoshibayashi, Seiji Satoh, Yoshiharu Sakai, Toru Nakano, Tsutomu Chiba.   

Abstract

Activation of tyrosine kinases is an important factor during cancer development. Axl, one of the receptor tyrosine kinases, binds to the specific ligand growth arrest-specific gene 6 (Gas6), which encodes a vitamin K-dependent gamma-carboxyglutamyl protein. Although many receptor tyrosine kinases and their ligands are involved in gastric carcinogenesis, whether Gas6-Axl signaling is involved in gastric carcinogenesis has not been elucidated. The aim of this study was to investigate the expression of Gas6 and Axl in gastric cancer and also their roles during gastric carcinogenesis. mRNA and protein of Gas6 and Axl were highly expressed in a substantial proportion of human gastric cancer tissue and cell lines, and Gas6 expression was significantly associated with lymph node metastasis. With recombinant Gas6 and a decoy-receptor of Axl in vitro, we demonstrated that Gas6-Axl signaling pathway enhanced cellular survival and invasion and suppressed apoptosis via Akt pathway. Our results suggests that Gas6-Axl signaling plays a role during gastric carcinogenesis, and that targeting Gas6-Axl signaling could be a novel therapeutic for gastric cancer. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186543     DOI: 10.1002/mc.20211

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

Review 1.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

2.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Authors:  Alexis Mollard; Steven L Warner; Lee T Call; Mark L Wade; Jared J Bearss; Anupam Verma; Sunil Sharma; Hariprasad Vankayalapati; David J Bearss
Journal:  ACS Med Chem Lett       Date:  2011-12-08       Impact factor: 4.345

3.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Authors:  Alvarez Hector; Elizabeth A Montgomery; Collins Karikari; Marcia Canto; Kerry B Dunbar; Jean S Wang; Georg Feldmann; Seung-Mo Hong; Michael C Haffner; Alan K Meeker; Sacha J Holland; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Dane Goff; Rajinder Singh; Juan Carlos Roa; Arivusudar Marimuthu; Gregory J Riggins; James R Eshleman; Barry D Nelkin; Akhilesh Pandey; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

4.  KLF5 and MYC modulated LINC00346 contributes to gastric cancer progression through acting as a competing endogeous RNA and indicates poor outcome.

Authors:  Tong-Peng Xu; Pei Ma; Wen-Yu Wang; You Shuai; Yan-Fen Wang; Tao Yu; Rui Xia; Yong-Qian Shu
Journal:  Cell Death Differ       Date:  2019-02-15       Impact factor: 15.828

5.  Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injury.

Authors:  Laura Llacuna; Cristina Bárcena; Lola Bellido-Martín; Laura Fernández; Milica Stefanovic; Montserrat Marí; Carmen García-Ruiz; José C Fernández-Checa; Pablo García de Frutos; Albert Morales
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

6.  Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Apurva R Patel; Rakesh Singh; Roger Mercer; Mandip Singh
Journal:  Pharm Res       Date:  2015-08-19       Impact factor: 4.200

7.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

8.  Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.

Authors:  C-W Chien; P-C Hou; H-C Wu; Y-L Chang; S-C Lin; S-C Lin; B-W Lin; J-C Lee; Y-J Chang; H S Sun; S-J Tsai
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

9.  Gene expression profile in colon cancer cells with respect to XIAP expression status.

Authors:  Liang Qiao; Gloria H Y Li; Yun Dai; Jide Wang; Zesong Li; Bing Zou; Qing Gu; Juan Ma; R Pang; Hui Y Lan; Benjamin C Y Wong
Journal:  Int J Colorectal Dis       Date:  2008-08-13       Impact factor: 2.571

10.  Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.

Authors:  Anna Gustafsson; Anna-Karin Boström; Börje Ljungberg; Håkan Axelson; Björn Dahlbäck
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.